CVRX Stock Gains on Unveiling of Barostim's Positive Study Data

CVRx (CVRX) recently announced the publication of new data supporting its Barostim technology for treating heart failure. The data was published in the Journal of the American College of Cardiology: Heart Failure. The publication builds on the data from the BeAT-HF trial published in 2024 in the European Journal of Heart Failure, demonstrating the long-term sustained symptomatic benefits of Barostim in heart failure patients with reduced ejection fraction. Shares of CVRX gained 3.2% on Friday on the announc ...